Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Blueprint Medicines develops potent and selective RET inhibitors for cancer

May 5, 2016

ROS1 inhibitor DS-6051 well tolerated in first-in-human study

May 5, 2016

Bayer describes novel radioimmunoconjugate BAY-1862864 entering phase I development

May 4, 2016

GlaxoSmithKline quadrivalent influenza vaccine safe, immunogenic in children under 3 years old

May 4, 2016

Phase II dose of bispecific antibody MCLA-128 defined in first-in-human solid tumor study

May 4, 2016

INCB-059872 demonstrates promising in vitro and in vivo activity in models of AML

May 4, 2016

Novel benzylpyrazole-based BUB1 kinase inhibitors with antitumor activity

May 4, 2016

Rigel identifies MerTK inhibitors for treating cancer

May 3, 2016

Novel anti-CD352 ADC SGN-CD352A

May 3, 2016

Arenavirus entry inhibitor from Kineta shows preclinical efficacy

May 3, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...